Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 2/2015

01-04-2015 | Osteoporosis and Cancer (P Clezardin and G van der Pluijm, Section Editors)

Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

Authors: Ashwani Garg, Kim Leitzel, Suhail Ali, Allan Lipton

Published in: Current Osteoporosis Reports | Issue 2/2015

Login to get access

Abstract

Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.
Literature
1.
Body J-J. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21 Suppl 7:vii180–5.PubMed
2.•
Vanderwalde A, Hurria A. Aging and osteoporosis in breast and prostate cancer. Cancer J Clin. 2011;61(3):139–56. It shows how cancer may cause decreases in bone mineral density and an increased risk of debilitating fracture.CrossRef
3.
Pfeilschifter J, DielI J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–93.PubMed
4.•
Reuss-Borst M, Hartmann U, Scheede C, Weiß J. Prevalence of osteoporosis among cancer patients in Germany. Osteoporos Int. 2012;23(4):1437–44. Higher prevalence of osteoporosis in cancer patients—this article is important as it mentions the many cases of osteoporosis in cancer patients.CrossRefPubMed
5.
National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: breast cancer, version 3. www.​nccn.​org. Accessed 15 May 2014
6.
National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: prostate cancer, version 2. www.​nccn.​org. Accessed 15 May 2014
7.
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288(15):1889–97.CrossRefPubMed
8.
Cameron DA, Douglas S, Brown JE, Anderson RA. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat. 2010;123(3):805–14.CrossRefPubMed
9.
Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990;61(2):308–10.CrossRefPubMedCentralPubMed
10.
11.
Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Nat Compr Cancer Netw. 2009;7(7):S1–29. quiz S30.
12.
Kodama H, Nose M, Niida S, et al. Essential role of macrophage colony stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 1991;173:1291–4.CrossRefPubMed
13.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.CrossRefPubMed
14.••
Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2010;2012(6):287–303. Role of denosumab in prevention of vertebral fractures and increasing bone mineral density in cancer treatment-induced bone loss.
15.
16.
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline, update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Am Soc Clin Oncol J Clin Oncol. 2010;28(23):3784–96.CrossRef
17.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours, recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.CrossRefPubMed
18.
Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426–34.CrossRefPubMedCentralPubMed
19.
Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336–42.CrossRefPubMed
20.
Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416–24.CrossRefPubMed
21.
Hines SL, Mincey BA, Sloan JA, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009;27:1047–53.CrossRefPubMedCentralPubMed
22.
Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res. 2010;12:R24.CrossRefPubMedCentralPubMed
23.
Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967–75.CrossRefPubMed
24.
Ishizaka K, Machida T, Kobayashi S, et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol. 2007;14:1071–5.CrossRefPubMed
25.
Kearns AE, Northfelt DW, Dueck AC, et al. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010;18:321–8.CrossRefPubMedCentralPubMed
26.•
27.
Merck, Co I. Fosamax (alendronate sodium) tablets and oral solution full prescribing information. 2011.
28.
Warner Chilcott Company L. Actonel (risedronate sodium) tablets full prescribing information. 2011.
29.
Roche Laboratories I. Boniva (ibandronate sodium) tablets and solution for infection, full prescribing information. 2011.
30.
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.CrossRefPubMed
31.
Hines SL, Mincey B, Dentchev T, et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009;117:603–9.CrossRefPubMedCentralPubMed
32.
Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972–8. discussion 978.CrossRefPubMed
33.
Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008;26:4739–45.CrossRefPubMedCentralPubMed
34.
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–8.CrossRefPubMed
35.
Bertoldo F, Tonini G, Vincenzi B, et al. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. Nat Rev Clin Oncol. 2009;6:191–2.CrossRefPubMed
36.
Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77–85.CrossRefPubMed
37.
Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21:2188–94.CrossRefPubMed
38.•
Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47:683–9. This study is relevant to prove benefits of zoledronic acid.CrossRefPubMedCentralPubMed
39.
Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271–7.CrossRefPubMed
40.
Hershman DL, McMahon DJ, Crew KD, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab. 2010;95:559–66.CrossRefPubMedCentralPubMed
41.
Hines SL, Sloan JA, Atherton PJ, et al. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010;19:92–6.CrossRefPubMedCentralPubMed
42.
Campbell SC, Bhoopalam N, Moritz TE, et al. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology. 2010;75:1138–43.CrossRefPubMed
43.
Casey R, Gesztesi Z, Rochford J. Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol. 2010;17:5170–7.PubMed
44.
Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66:1054–9.CrossRefPubMed
45.
Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.CrossRefPubMed
46.
Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182:2257–64.CrossRefPubMed
47.
Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.CrossRefPubMed
48.
Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 2008;112:1001–10.CrossRefPubMed
49.
Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) injection. 2011.
50.
Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–6.CrossRefPubMed
51.
Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152–5.CrossRefPubMedCentralPubMed
52.
Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316–21.CrossRefPubMedCentralPubMed
53.
54.
Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185:17–23.CrossRefPubMed
55.
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–5.CrossRefPubMed
56.
Novartis Pharmaceuticals Corporation. Miacalcin (calcitonin salmon) (injection or nasal spray) full prescribing information. 2011.
57.
Eli Lilly and Company. Forteo (teriparatide injection) full prescribing information. 2010.
58.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.CrossRefPubMed
59.
Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510–6.CrossRefPubMed
60.
Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.CrossRefPubMed
61.
Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009;182:2670–5.CrossRefPubMedCentralPubMed
62.•
Smith MR, Saad F, Egerdie B, et al. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011;26:2827–33. There is rapid decline in bone turnover markers in patient on androgen deprivation therapy for prostate cancer receiving denosumab. That may be relevant to monitor the response of denosumab.CrossRefPubMedCentralPubMed
63.
Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118:81–7.CrossRefPubMed
64.
Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health-Syst Pharm. 2006;63:534–46.CrossRefPubMed
65.
Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Nat Compr Cancer Netw. 2009;7(3):S1–32. quiz S33–5.
Metadata
Title
Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss
Authors
Ashwani Garg
Kim Leitzel
Suhail Ali
Allan Lipton
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 2/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0252-x

Other articles of this Issue 2/2015

Current Osteoporosis Reports 2/2015 Go to the issue

Rare Bone Disease (CB Langman and E Shore, Section Editors)

Hypophosphatemic Rickets: Lessons from Disrupted FGF23 Control of Phosphorus Homeostasis

Rare Bone Disease (CB Langman and E Shore, Section Editors)

Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action

Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

Diabetes, Diabetic Complications, and Fracture Risk

Osteocytes (T Bellido and J Klein-Nulend, Section Editors)

Cx43 and Mechanotransduction in Bone

Nutrition, Exercise, and Lifestyle in Osteoporosis (CM Weaver and R Daly, Section Editors)

Diet, Gut Microbiome, and Bone Health

Kidney and Bone (SM Moe and IB Salusky, Section Editors)

Defective Skeletal Mineralization in Pediatric CKD